Cargando…

A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer

BACKGROUND: Medical image analysis has evolved to facilitate the development of methods for high-throughput extraction of quantitative features that can potentially contribute to the diagnostic and treatment paradigm of cancer. There is a need for further improvement in the accuracy of predictive ma...

Descripción completa

Detalles Bibliográficos
Autores principales: McAnena, Peter, Moloney, Brian M., Browne, Robert, O’Halloran, Niamh, Walsh, Leon, Walsh, Sinead, Sheppard, Declan, Sweeney, Karl J., Kerin, Michael J., Lowery, Aoife J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789647/
https://www.ncbi.nlm.nih.gov/pubmed/36564734
http://dx.doi.org/10.1186/s12880-022-00956-6
_version_ 1784859000122114048
author McAnena, Peter
Moloney, Brian M.
Browne, Robert
O’Halloran, Niamh
Walsh, Leon
Walsh, Sinead
Sheppard, Declan
Sweeney, Karl J.
Kerin, Michael J.
Lowery, Aoife J.
author_facet McAnena, Peter
Moloney, Brian M.
Browne, Robert
O’Halloran, Niamh
Walsh, Leon
Walsh, Sinead
Sheppard, Declan
Sweeney, Karl J.
Kerin, Michael J.
Lowery, Aoife J.
author_sort McAnena, Peter
collection PubMed
description BACKGROUND: Medical image analysis has evolved to facilitate the development of methods for high-throughput extraction of quantitative features that can potentially contribute to the diagnostic and treatment paradigm of cancer. There is a need for further improvement in the accuracy of predictive markers of response to neo-adjuvant chemotherapy (NAC). The aim of this study was to develop a radiomic classifier to enhance current approaches to predicting the response to NAC breast cancer. METHODS: Data on patients treated for breast cancer with NAC prior to surgery who had a pre-NAC dynamic contrast enhanced breast MRI were included. Response to NAC was assessed using the Miller–Payne system on the excised tumor. Tumor segmentation was carried out manually under the supervision of a consultant breast radiologist. Features were selected using least absolute shrinkage selection operator regression. A support vector machine learning model was used to classify response to NAC. RESULTS: 74 patients were included. Patients were classified as having a poor response to NAC (reduction in cellularity < 90%, n = 44) and an excellent response (> 90% reduction in cellularity, n = 30). 4 radiomics features (discretized kurtosis, NGDLM contrast, GLZLM_SZE and GLZLM_ZP) were identified as pertinent predictors of response to NAC. A SVM model using these features stratified patients into poor and excellent response groups producing an AUC of 0.75. Addition of estrogen receptor status improved the accuracy of the model with an AUC of 0.811. CONCLUSION: This study identified a radiomic classifier incorporating 4 radiomics features to augment subtype based classification of response to NAC in breast cancer.
format Online
Article
Text
id pubmed-9789647
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97896472022-12-25 A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer McAnena, Peter Moloney, Brian M. Browne, Robert O’Halloran, Niamh Walsh, Leon Walsh, Sinead Sheppard, Declan Sweeney, Karl J. Kerin, Michael J. Lowery, Aoife J. BMC Med Imaging Research BACKGROUND: Medical image analysis has evolved to facilitate the development of methods for high-throughput extraction of quantitative features that can potentially contribute to the diagnostic and treatment paradigm of cancer. There is a need for further improvement in the accuracy of predictive markers of response to neo-adjuvant chemotherapy (NAC). The aim of this study was to develop a radiomic classifier to enhance current approaches to predicting the response to NAC breast cancer. METHODS: Data on patients treated for breast cancer with NAC prior to surgery who had a pre-NAC dynamic contrast enhanced breast MRI were included. Response to NAC was assessed using the Miller–Payne system on the excised tumor. Tumor segmentation was carried out manually under the supervision of a consultant breast radiologist. Features were selected using least absolute shrinkage selection operator regression. A support vector machine learning model was used to classify response to NAC. RESULTS: 74 patients were included. Patients were classified as having a poor response to NAC (reduction in cellularity < 90%, n = 44) and an excellent response (> 90% reduction in cellularity, n = 30). 4 radiomics features (discretized kurtosis, NGDLM contrast, GLZLM_SZE and GLZLM_ZP) were identified as pertinent predictors of response to NAC. A SVM model using these features stratified patients into poor and excellent response groups producing an AUC of 0.75. Addition of estrogen receptor status improved the accuracy of the model with an AUC of 0.811. CONCLUSION: This study identified a radiomic classifier incorporating 4 radiomics features to augment subtype based classification of response to NAC in breast cancer. BioMed Central 2022-12-23 /pmc/articles/PMC9789647/ /pubmed/36564734 http://dx.doi.org/10.1186/s12880-022-00956-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
McAnena, Peter
Moloney, Brian M.
Browne, Robert
O’Halloran, Niamh
Walsh, Leon
Walsh, Sinead
Sheppard, Declan
Sweeney, Karl J.
Kerin, Michael J.
Lowery, Aoife J.
A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer
title A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer
title_full A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer
title_fullStr A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer
title_full_unstemmed A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer
title_short A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer
title_sort radiomic model to classify response to neoadjuvant chemotherapy in breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789647/
https://www.ncbi.nlm.nih.gov/pubmed/36564734
http://dx.doi.org/10.1186/s12880-022-00956-6
work_keys_str_mv AT mcanenapeter aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT moloneybrianm aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT brownerobert aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT ohalloranniamh aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT walshleon aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT walshsinead aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT shepparddeclan aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT sweeneykarlj aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT kerinmichaelj aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT loweryaoifej aradiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT mcanenapeter radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT moloneybrianm radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT brownerobert radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT ohalloranniamh radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT walshleon radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT walshsinead radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT shepparddeclan radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT sweeneykarlj radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT kerinmichaelj radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer
AT loweryaoifej radiomicmodeltoclassifyresponsetoneoadjuvantchemotherapyinbreastcancer